Noteworthy Buzzers: Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), United Rentals, Inc. (NYSE:URI)

A month ago, analyst EPS consensus estimated earnings of US$1.25 per share.

A number of other equities analysts have also commented on ALXN. FBR & Co raised Alexion Pharmaceuticals from an "underperform" rating to a "market perform" rating and set a $130.00 price target for the company in a report on Friday, October 28th. Analysts set a 12-month price target of $37.48 a share. The consensus recommendation by Thomson Reuters analysts is Outperform and their mean rating for the stock is 1.90 on scale of 1-5.

12/13/2016 - Alexion Pharmaceuticals, Inc. had its "hold" rating reiterated by analysts at Jefferies. The company has a 1 Year high price target of $167.93.

Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 136.91 on Thursday.

In related news, EVP John B. Moriarty sold 1,044 shares of Alexion Pharmaceuticals stock in a transaction on Monday, December 12th. The stock is now moving above its 20-Day Simple Moving Average of 0.22% with the 50-Day Simple Moving Average of 0.22 percent.

The company forecast 2017 adjusted Soliris revenue in the range of $3.03 billion to $3.10 billion.

Alexion Pharmaceuticals Inc.'s fourth-quarter profits increased by more than a third thanks to higher sales of its drugs created to treat rare diseases and cancer. California State Teachers Retirement System now owns 460,324 shares of the biopharmaceutical company's stock valued at $53,747,000 after buying an additional 1,946 shares during the last quarter.

Snap-on Incorporated (NYSE:SNA) board of directors declared a quarterly common stock dividend of $0.71 per share payable March 10, 2017 to shareholders of record on February 24, 2017. The firm had revenue of $799 million for the quarter, compared to analyst estimates of $787.07 million. During the same period in the prior year, the company earned $1.13 earnings per share. Over the last five days, shares have managed 4.46% gains and now is up 2.34% since hitting its 200-day moving average of $127.06.

11/10/2016 - Alexion Pharmaceuticals, Inc. had its "overweight" rating reiterated by analysts at JP Morgan. If you are viewing this story on another site, it was copied illegally and reposted in violation of USA and worldwide copyright & trademark legislation. Credit Suisse Group AG's price objective indicates a potential upside of 34.47% from the stock's previous close. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The shares were sold at an average price of $118.61, for a total value of $123,828.84. Following the sale, the director now directly owns 438,497 shares in the company, valued at approximately $60,723,064.56. The disclosure for this sale can be found here. Its last month's stock price volatility remained 1.35% which for the week approaches 1.4. LPL Financial LLC boosted its position in shares of Alexion Pharmaceuticals by 75.2% in the third quarter. The Market Cap of the company stands at 29.13 Billion.

Earnings: Alexion missed on earnings expectations in the fourth quarter of 2016. The company provides variable, universal, term, and whole life products; individual disability income products; personal lines property and casualty insurance, including private passenger automobile, homeowners, and personal excess liability insurance; and variable and fixed annuities for asset accumulation and distribution needs, as well as mutual funds and other securities products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment.

Related:

Comments